Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
KELNOR 1/50 vs ALYACEN 7/7/7
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination hormonal contraceptive: ethinyl estradiol provides estrogenic activity, suppressing gonadotropin release; norethindrone acetate provides progestational activity, inhibiting ovulation and causing cervical mucus thickening.
Combination of norethindrone (progestin) and ethinyl estradiol (estrogen) that inhibits gonadotropin release from the pituitary, suppressing ovulation, increasing cervical mucus viscosity, and altering endometrial receptivity.
Oral contraception
Prevention of pregnancy
One tablet (norethindrone 1 mg/ethinyl estradiol 50 mcg) orally once daily, taken at the same time each day for 21 days, followed by 7 days of placebo.
ALYACEN 7/7/7 is a combination oral contraceptive containing ethinyl estradiol 0.02 mg and drospirenone 3 mg. One tablet taken orally once daily for 28 days (7 active, 7 placebo, 7 active) without a hormone-free interval.
Ethinyl estradiol: biphasic, terminal half-life 13-27 hours (mean ~17 h); norethindrone: monoexponential, half-life 5-14 hours (mean ~8 h). Steady-state achieved after 3-5 days. Accumulation may occur in patients with hepatic impairment.
Terminal elimination half-life is 14 hours (range 12-16 h) in healthy adults; prolonged to 24-30 h in moderate renal impairment (Cr Cl 30-50 m L/min).
Hepatic via CYP3A4 (ethinyl estradiol) and various reductases (norethindrone acetate); undergoes extensive first-pass metabolism.
Norethindrone: primarily hepatic via reduction and conjugation, with CYP3A4 involvement. Ethinyl estradiol: primarily via CYP3A4, also undergoes sulfation and glucuronidation.
Renal: ~50% (as metabolites, primarily ethinyl estradiol glucuronide and sulfate conjugates; norethindrone metabolites). Fecal: ~35% (biliary excretion of conjugates followed by hydrolysis and elimination). Unchanged drug: <5%.
Renal: ~50% (unchanged drug); Fecal: ~20% (via bile); Biliary: ~30% (metabolites). Total clearance is 12 L/h.
Ethinyl estradiol: ~97% bound to albumin (specific binding to SHBG). Norethindrone: ~92% bound to albumin and SHBG.
98% bound primarily to albumin; minor binding to alpha-1-acid glycoprotein.
Ethinyl estradiol: 2-4 L/kg (distributes widely into body tissues, including breast, liver, adipose, and reproductive organs). Norethindrone: 3-5 L/kg (extensive distribution).
0.35 L/kg (total body water distribution); in obesity, Vd increases to 0.5 L/kg due to lipophilicity.
Oral: Ethinyl estradiol ~40-45% (due to first-pass metabolism in gut wall and liver); norethindrone ~50-60% (presystemic metabolism).
Oral: 85% (with high-fat meal reduces to 70%); Sublingual: 90%.
No dose adjustment required for mild to moderate renal impairment. For severe renal impairment (GFR <30 m L/min) or end-stage renal disease, use is generally not recommended due to potential fluid retention and hyperkalemia; consider alternative contraception.
Contraindicated in patients with severe renal impairment (Cr Cl <30 m L/min) or acute renal failure due to drospirenone's antimineralocorticoid activity. No dose adjustment recommended for mild to moderate impairment (Cr Cl ≥30 m L/min).
Contraindicated in acute hepatic disease or decompensated cirrhosis (Child-Pugh class B or C). For mild hepatic impairment (Child-Pugh class A), no dose adjustment; use with caution and monitor liver function.
Contraindicated in patients with acute hepatic disease, hepatic tumors, or impaired liver function (Child-Pugh class B or C). Discontinue if jaundice or pruritus develops. No dose adjustment for Child-Pugh class A.
Not indicated for use in pediatric patients before menarche. For adolescent females post-menarche, same dosing as adults: one tablet orally daily per 21-day cycle.
Not indicated for use in pediatric patients before menarche. Safety and efficacy in postmenarchal adolescents are expected to be similar to adults; dose is same as adults.
Not indicated for use in postmenopausal women. No specific geriatric dose adjustments; evaluate cardiovascular and thromboembolic risks prior to use in women over age 35 who smoke or have risk factors.
Not indicated for use in postmenopausal women. No recommendations for geriatric population due to lack of indication.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptives. Risk increases with age and smoking severity (particularly in women >35 years). Women who use COCs should be strongly advised not to smoke.
Cigarette smoking increases risk of serious cardiovascular events from combined oral contraceptives (COCs). Risk increases with age and amount smoked (especially >15 cigarettes/day). Women over 35 who smoke should not use COCs.
Thromboembolic disorders (DVT, PE, stroke, MI),Vascular disease in diabetes mellitus,Hypertension,Gallbladder disease,Hepatic neoplasia,Carbohydrate/lipid effects,Ocular lesions (retinal thrombosis),Bleeding irregularities,Depression,Use in women with hereditary angioedema
Thrombotic disorders (thrombophlebitis, pulmonary embolism, cerebral hemorrhage, myocardial infarction),Cerebrovascular disease,Carcinoma of the breast or reproductive organs,Hepatic adenoma or carcinoma,Ocular lesions (retinal thrombosis, papilledema),Gallbladder disease,Carbohydrate/lipid effects,Elevated blood pressure,Hereditary angioedema,Chloasma,Hepatic impairment
Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease (current or history),Known or suspected carcinoma of the breast or endometrium,Undiagnosed abnormal genital bleeding,Pregnancy or suspected pregnancy,Jaundice or hepatocellular disease with cholestasis (current or history),Heavy smoking (≥15 cigarettes/day) in women >35 years,Hepatic adenoma or carcinoma,Known or suspected estrogen-dependent neoplasia
Breast cancer (current or history),Undiagnosed abnormal genital bleeding,Known or suspected pregnancy,Current or history of thrombotic disorders (DVT, PE, stroke, MI),Cerebrovascular or coronary artery disease,Valvular heart disease with complications,Severe hypertension,Diabetes with vascular disease,Headaches with focal neurological symptoms (e.g., migraine with aura),Major surgery with prolonged immobilization,Known thrombophilia (e.g., Factor V Leiden, prothrombin mutation, protein S/C deficiency),Active liver disease (tumors, hepatitis, cirrhosis),Uncontrolled hypertension,Smoking (if age >35),Hypersensitivity to any component
No specific food interactions. Grapefruit juice may modestly increase ethinyl estradiol levels but not clinically significant. St. John's Wort and some herbal supplements may reduce efficacy; avoid concurrent use. Maintain consistent diet if taken with food to avoid gastrointestinal upset.
Grapefruit and grapefruit juice may increase ethinyl estradiol levels, potentially increasing side effects. St. John's wort (herbal supplement) can reduce contraceptive efficacy. No other significant food interactions; however, maintaining a stable intake of vitamin C and folate is generally recommended.
FDA Pregnancy Category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: Use is associated with cardiovascular defects, limb reduction defects, and neural tube defects. Second and third trimesters: Risk of feminization of male fetus, urogenital anomalies, and other congenital anomalies. Postnatal effects include behavioral and intellectual developmental issues.
ALYACEN 7/7/7 contains ethinylestradiol and norethindrone. First trimester: No increased risk of major birth defects based on epidemiologic studies; however, inadvertent use does not warrant termination. Second and third trimesters: Avoid use due to potential adverse effects on fetal development, including feminization of male fetuses and potential for congenital anomalies from progestin. Postnatal: Possible long-term effects on reproductive development.
Norethindrone (progestin) and mestranol (estrogen) are excreted into breast milk. M/P ratio for norethindrone is approximately 0.5–0.6. Mestranol is metabolized to ethinyl estradiol, with limited data on excretion. Breastfeeding is generally not recommended during use; may reduce milk production and quality. Avoid use in breastfeeding women due to potential adverse effects on infant.
Contraindicated in breastfeeding. Ethinylestradiol reduces milk quantity and quality. Norethindrone is excreted in low amounts (M/P ratio approximately 0.3-0.4). However, combination oral contraceptives are not recommended during lactation due to estrogen effects on milk production.
Contraindicated in pregnancy; no dose adjustment guidelines exist because use is not recommended. If inadvertent exposure occurs, discontinue drug immediately; no pharmacokinetic-based dose adjustments are applicable.
ALYACEN 7/7/7 is contraindicated in pregnancy; no dose adjustments are applicable as use is not recommended. Pharmacokinetic changes in pregnancy (increased clearance of steroids) would theoretically require higher doses, but due to fetal risks, alternative therapies should be used.
KELNOR 1/50 is a combination oral contraceptive containing ethinyl estradiol 50 mcg and norethindrone 1 mg. It has a higher estrogen dose than modern low-dose pills, increasing thrombotic risk. Use with caution in smokers over 35, hypertensive patients, and those with migraines with aura. Consider alternative contraception in women with BMI > 30 due to possible efficacy reduction. Monitor for breakthrough bleeding and ensure no missed doses to maintain contraceptive efficacy.
ALYACEN 7/7/7 is a triphasic oral contraceptive containing ethinyl estradiol and norgestimate. The 7/7/7 regimen refers to the varying doses of norgestimate across three 7-day phases (0.18 mg, 0.215 mg, 0.25 mg) with a fixed 0.025 mg ethinyl estradiol. Use consistent 7-day placebo interval. Consider increased risk of venous thromboembolism (VTE) in patients with BMI >30, smoking >15 cigarettes/day, or age >35. Monitor for breakthrough bleeding, especially during the first 3 cycles. Avoid in patients with migraine with aura, uncontrolled hypertension, or history of DVT/PE. Drug interactions with CYP3A4 inducers (e.g., rifampin, carbamazepine) may reduce efficacy; consider backup contraception.
Take one pill daily at the same time each day, even if no intercourse occurs.,If you miss a pill, follow the package instructions; use backup contraception if needed.,Do not smoke while taking this medication, especially if over 35, due to increased risk of blood clots.,Report any signs of blood clots: sudden leg pain, chest pain, shortness of breath, or sudden severe headache.,This medication does not protect against HIV or other sexually transmitted infections.,Common side effects include nausea, headache, breast tenderness, and breakthrough bleeding in the first few months.
Take one pill daily at the same time each day, in the order specified on the pack (active pills followed by placebo).,If you miss a pill, follow the package instructions; missing pills increases pregnancy risk, especially if placebo week is extended.,Common side effects include nausea, headache, breast tenderness, and spotting, which usually improve after 2-3 cycles.,Seek immediate medical attention for severe abdominal pain, chest pain, shortness of breath, leg pain/swelling, or severe headache.,This medication does not protect against HIV/AIDS or other sexually transmitted infections (STIs).,Inform your healthcare provider if you smoke, as smoking increases risk of serious cardiovascular side effects, especially if over 35 years.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about KELNOR 1/50 vs ALYACEN 7/7/7, answered by our medical review team.
KELNOR 1/50 is a Oral Contraceptive that works by Combination hormonal contraceptive: ethinyl estradiol provides estrogenic activity, suppressing gonadotropin release; norethindrone acetate provides progestational activity, inhibiting ovulation and causing cervical mucus thickening.. ALYACEN 7/7/7 is a Oral Contraceptive that works by Combination of norethindrone (progestin) and ethinyl estradiol (estrogen) that inhibits gonadotropin release from the pituitary, suppressing ovulation, increasing cervical mucus viscosity, and altering endometrial receptivity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between KELNOR 1/50 and ALYACEN 7/7/7 depend on the specific clinical indication. These are both Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of KELNOR 1/50 is: One tablet (norethindrone 1 mg/ethinyl estradiol 50 mcg) orally once daily, taken at the same time each day for 21 days, followed by 7 days of placebo.. The standard adult dose of ALYACEN 7/7/7 is: ALYACEN 7/7/7 is a combination oral contraceptive containing ethinyl estradiol 0.02 mg and drospirenone 3 mg. One tablet taken orally once daily for 28 days (7 active, 7 placebo, 7 active) without a hormone-free interval.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between KELNOR 1/50 and ALYACEN 7/7/7 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. KELNOR 1/50 is classified as Category C. FDA Pregnancy Category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: Use is associated with cardiovascular defects, limb reduction defects, and neural. ALYACEN 7/7/7 is classified as Category C. ALYACEN 7/7/7 contains ethinylestradiol and norethindrone. First trimester: No increased risk of major birth defects based on epidemiologic studies; however, inadvertent use does n. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.